A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
Founder of telehealth startup Done sentenced to six years in prison for Adderall fraud scheme
fiercehealthcare - Ruthia He, the founder and former chief executive officer of telehealth startup Done Global, was sentenced to six years in prison on Tuesday and fined $1 million in connection with an Adderall fraud scheme.
AI Summary: A federal judge sentenced the founder of a telehealth startup to six years in prison following conviction in an Adderall‑prescribing fraud scheme. Regulators and prosecutors say the case exposes how virtual care can be gamed to fuel illegal controlled‑substance distribution, and the verdict signals tougher enforcement is coming for bad actors hiding behind telemedicine’s convenience.
Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.
First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients
medicalxpress - Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged in the past two decades, un…
AI Summary: A first‑in‑human immunotherapy study in recurrent glioblastoma reported a more than twofold improvement in progression‑free survival, drawing attention to anti‑LAG‑3 strategies with or without anti‑PD‑1. While early and limited, the results provide a rare hint of efficacy in a notoriously treatment‑resistant cancer and warrant expedited follow‑up.
Tampa General sues Eli Lilly over pulled 340B discounts
Ella Jeffries / beckershospitalreview - Tampa General (Fla.) Hospital has sued Eli Lilly and Lilly USA, alleging the drugmaker’s decision to cut off the hospital’s 340B pricing access violates Florida’s Deceptive and Unfair Trade Practices Act. According to the July 2 complaint, filed in the U.…
AI Summary: Tampa General Hospital has filed suit against Eli Lilly after the company suspended discounts tied to the 340B drug-pricing program, alleging the move harmed hospitals that rely on those savings to fund patient care. The litigation highlights ongoing tensions over manufacturer discount policies and financial pressures on safety-net providers.
Thousands of Medicare Beneficiaries Thought Their Drug Plan Was Free. Then They Lost It.
Susan Jaffe / kffhealthnews - Thousands of people who had a Medicare drug plan with zero-dollar premiums last year got small premium increases this year — and didn’t know it. They were dropped from their coverage for failing to pay amounts as little as $8, and most can’t get it again …
AI Summary: Investigations reveal that many Medicare beneficiaries who believed their drug coverage was free later discovered they had lost benefits, often because of plan changes or confusing enrollment processes. The situation exposed gaps in consumer communication and program oversight, prompting calls for clearer disclosures and stronger safeguards to prevent future coverage surprises.
Meningococcal B vaccine ineffective in gonorrhea prevention for men who have sex with men
medicalxpress - The meningococcal B vaccine is ineffective in gonorrhea prevention among men who have sex with men (MSM) at high risk of infection, according to findings from the world's largest randomized controlled trial (RCT) into possible efficacy published in the Ne…
AI Summary: A major study found that the meningococcal B (MenB) vaccine does not provide protection against gonorrhea in men who have sex with men, contradicting earlier hopes that cross-protection might exist. Researchers emphasize the need for dedicated gonorrhea vaccines and continued public-health measures to control rising infection rates.